Trial Profile
A Phase III, Double-blind, Randomized, Placebo-controlled Multi-centre, Study to Assess the Efficacy and Safety of AZD9291 Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2023
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Adenocarcinoma; Adenosquamous carcinoma; Carcinoma; Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms ADAURA
- Sponsors AstraZeneca
- 25 Jul 2023 Planned End Date changed from 30 Jun 2023 to 31 Dec 2030.
- 06 Jun 2023 Results of final overall survival (OS) analysis from ADAURA, presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 04 Jun 2023 Final results assessing the efficacy (overall survival) of osimertinib in resected EGFR-mutated non-small-cell lung cancer, published in the New England Journal of Medicine.